Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate versus topiramate and levetiracetam for adjunctive treatment of partial-onset seizures
ACTRN12609000600246Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in epilepsy and Focal onset seizure comparing Carisbamate adjunctive therapy, Topiramate adjunctive therapy and Levetiracetam adjunctive therapy (3 arms). Primary endpoint: Time to discontinuation of study medication. Started Nov 2007; status: terminated.
02
Drugs
carisbamatetopiramatelevetiracetam
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on ACTRN12609000600246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000600246.